Novavax
Who?
Novavax is based in Gaithersburg, Md. It was founded in 1987, but is only now preparing to launch actual vaccines (also including a flu vaccine called NanoFlu). Before the pandemic, it appeared to be in a downward spiral owing to repeated failures of its vaccine candidates. The company received $1.6 billion from the Trump administration’s Operation Warp Speed and $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund its COVID vaccine.
Vaccine name and type?
The Novavax COVID-19 vaccine, or NVX-CoV2373, or Covovax in its Indian trials. Novavax calls it a recombinant nanoparticle vaccine, and its production involves infecting moth cells with an insect virus that’s been modified to include the SARS-CoV-2 spike protein gene. The company says the vaccine has an efficacy rate of over 96%.
<a class="break-all" href="https://adclick.g.doubleclick.net/pcs/click?xai=AKAOjsvohM8N02O7yydRll9KUGJ04qQsVfi6PLfQCuSlqpffN-589Vfwjdx0b0cRL8sJ95pF5eoDyeo04thFSioOH84tdQXqc9J14bG9cZDuBpMKOiJO1DWoolL31XQD-EtBG00Ppo4_5EYvrVXy7zeHnA55hQK2cjmpROKbk8tIp0SmI2m5VdjZ7bjd4e8IyFIzCUIJ5ERKcs3-b-5Go9zDlz12nLU2elmXnhf7SKKShq4E8Lu3YBNGLV0LSTzkxlUpKBfuPrfTl0qPdkus4q9USHd7zELQq3dqPaRiswM5eTF06rLGaLTIPHxSfiPpjE6yE_FDRmhdCkd87cXGuLgZo9np816LBslpkFOMLV8UO5890V5uCtHybTFxns1rX-hLF2R29tfurXbUGLBbHki3EPq3W6UiGmOgQkTQ51NgiQ4u5dYOSmOrvih5T5HV-LPGGAcX0MPK915vPfy5n31wQmP2VwU64vx7eps1AJ6x3Y5adSJ3JkvFFNSCAk06HJGxm5HSV47AQ2ujzDufsypVmoiKv341JhUmnT_FzMOKpEsuGViedHgykGPrwNhsVD8KqM10NviFhmBktNBrVvP97o9SlPNyMB3Biqu2j56gF0w-PpuXk1zx-yFxDBcHypOD82MdT9ii51U2eB8CAepdv7qr4xzuGVBTfj977qSVDPHUhKHIjZYCzMKLxMDIBk2OrjZKcshjHjlHj6hlUEu3G1857NLakh4aen4SLkqQiq_MTWbejUSaNs02WFO6Lc0j1KdnL__yeALznePA2nwXnwaagMru5ZKFWBr-wYXwxg7byI34cbu9Gw34XaxemyX8S4HdTrv3y-QO6dgU-fqTe6cBnGkt6dEspQ5hJm7Wm8p9xnbNpgY3GaxETk-3JTDsmaUzg8vtTRG9bbWmY1QpVEFuOnLEacBk3HMF3A3XhU-GC44Zskh-m1O4gUZUvXi6_q93mPYMBTn4fBz5qedF3Kfh9-sHDtqjv212RcwQu64_BswNZp-r3O8VCWYMfI5lpnvwEE-wRmPDJK_u07GiPF5wRsYSSqyip7XF7muJuhoROPjVd49jMMIKRodDsJ6GoGptqiZK8IA-0k2AcEIhBpXYCSil-U-p6sucd3oIOUeaLHZTsm6P8iDIqJc07oB4eX3E9EzP9wu5cQ31XIHwr_-UncsaGvrr2f0598hs-ehuOGDXy1feNzuhU-vPRMJOwA&sai=AMfl-YRTYxSZqilFA7zzTG3tBz9xho-TbhNjntg4_JkCk0BZE19MRcP9Crz-xxfg-UuI0B0kJKEBr0uHX4ey9cJme9S8euKnGeDgcE51oPPs63V3WXxeQ8EaiP_-HKuOWhC57XrOUdt9ZhYJd9Y_o9xug1vsNsaJDSSqlC_tVu0_4YLXRGwZoQ&sig=Cg0ArKJSzDXrCKVcxkE1&fbs_aeid=%5Bgw_fbsaeid%5D&urlfix=1&adurl=www.taylorwimpey.co.uk/find-your-home/england/north-yorkshire/knaresborough/trinity-fields%3Futm_source%3Dprogrammatic%26utm_medium%3Dprogrammatic%2520display%26utm_campaign%3DTWNYTrinity%2520Fieldsprogrammatic%2520display" rel="nofollow" target="_blank">
When and where?
Novavax is hoping for imminent approval in the U.S., the U.K., Canada, South Korea and the EU. Its Warp Speed deal should see it deliver 100 million doses in the U.S., while it has a 60 million dose contract in the U.K. and a Canadian deal for up to 76 million doses. Novavax was supposed to sign an EU deal for up to 200 million doses, but according to the European side it’s dragging its heels owing to problems sourcing raw materials. The company will however be supplying 1.45 billion doses to the Covax facility for low- and middle-income countries. It will also sell 40 million doses to South Korea.
Can it deliver?
Novavax’s Covax contribution includes 350 million doses that it will make itself, as well as 1.1 billion to be produced by the Serum Institute of India (SII), the world’s biggest vaccine manufacturer. At full capacity, the SII deal is supposed to pump out more than 2 billion doses a year. Novavax has said its own recently acquired facilities in the Czech Republic will have a capacity of over 1 billion doses annually. It also has manufacturing deals with Fujifilm Diosynth Biotechnologies (FDB) in the U.S. (100 million doses) and in the U.K. (180 million doses annually), Biofabri in Spain (over half a million doses), SK Bioscience in South Korea (40 million doses), and Takeda in Japan (over 250 million doses a year).